Taysha Gene Therapies (TSHA) Misses Q3 EPS by 76c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mailGet Alerts TSHA Hot Sheet
Join SI Premium – FREE
Taysha Gene Therapies (NASDAQ: TSHA) reported Q3 EPS of ($0.93), $0.76 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $4.75 million versus the consensus estimate of $2.33 million.
For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Portillo's Inc. (PTLO) Tops Q3 EPS by 3c; Offers Guidance
- Tecnoglass (TGLS) Tops Q3 EPS by 2c ; Offers Guidance
- Shattuck Labs, Inc. (STTK) Misses Q3 EPS by 3c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
